EU Listing Act: What Market Participants Need to Know – Opportunities and a Timing Contradiction
- 19. Mai
- 1 Min. Lesezeit
Two documents now shape EU capital markets: Regulation (EU) 2024/2809 (Listing Act, Nov 2024) and ESMA’s public statement (May 7, 2026). The goal is less burden for issuers, especially SMEs. But a timing gap creates real uncertainty.
What the Listing Act introduces
Dual threshold – Offers under €12m (or €5m if a member state opts) over 12 months are exempt from an EU prospectus. National disclosures allowed but limited.
EU Follow-on Prospectus – For companies listed ≥18 months. Max 50 pages, streamlined review.
EU Growth Issuance Prospectus – For SMEs and small unlisted firms, up to €50m/12 months. Essential disclosures only (business, financials, risks, management, plus ESG if applicable).
Harmonisation & digitalisation – Standardised ESMA templates, electronic access, central repository.
Stricter risk disclosure – In all prospectuses: risks must be ranked by materiality, categorised, concise, with impact explanation. No generic risks.
The timing gap (ESMA statement)
The new Level 1 rules become binding on June 5, 2026. But the detailed Delegated Act (amending (EU) 2019/980) was adopted on May 7, 2026 and applies later. ESMA says: use the Delegated Act as practical guidance – yet it has no binding force.
Two contradictions to watch
Less information vs. stricter risks – The Act simplifies overall, but adds mandatory risk rankings and categorisations for every prospectus.
Binding rules without binding details – From June 5, you must follow the new law, but the official disclosure annexes are not yet in force. NCAs may diverge.
